A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776A in Patients With Alzheimer's Disease.
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs GSK 933776 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 23 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 23 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.